漫步
发表于 2025-3-23 12:05:38
CAR-T Cell Complicationsrelapsed and/or refractory B-cell malignancies. Multiple CD19-directed and now a B cell maturation antigen (BCMA) CAR T-cell therapies have been approved for use. Despite their differences, they all share the same toxicities and risks to patients. Cytokine release syndrome (CRS) and immune effector
颠簸下上
发表于 2025-3-23 16:18:14
Mechanisms of Resistance and Relapse After CAR-T Cell Therapynd real-world data, however, reveal that most patients will not achieve durable remission. Therapeutic failure appears to segregate into two distinct models: inherent resistance, in which there is no meaningful disease response after treatment, or acquired resistance, in which disease recurrence fol
Rotator-Cuff
发表于 2025-3-23 21:38:15
http://reply.papertrans.cn/39/3821/382002/382002_13.png
胆小懦夫
发表于 2025-3-24 00:11:12
http://reply.papertrans.cn/39/3821/382002/382002_14.png
蛰伏
发表于 2025-3-24 04:46:12
http://reply.papertrans.cn/39/3821/382002/382002_15.png
FLASK
发表于 2025-3-24 09:23:18
Mechanisms of Resistance and Relapse After CAR-T Cell Therapyusion or that develops after delivery to patients. In this chapter, we review the mechanistic and correlative studies investigating resistance to CAR-T cells, and discuss strategies designed to overcome this significant hurdle to the broader success of this therapy.
Commonwealth
发表于 2025-3-24 14:13:18
The History of Cellular Therapiesable achievements in medicine are built upon thousands of years of advancement in the understanding of cancer and immunity with rapid acceleration in the last few decades. In this chapter, we will broadly review historical aspects of gene and cellular therapy development, focusing on major milestones.
Gorilla
发表于 2025-3-24 17:01:44
http://reply.papertrans.cn/39/3821/382002/382002_18.png
Cardiac-Output
发表于 2025-3-24 19:02:08
Off-the-Shelf CAR-Ttherapies stem from utilizing autologous patient T cells as the starting material to generate CAR-T. Here we will describe the limitations of autologous CAR-T, the advantages and hurdles of allogeneic donor CAR-T, the learnings from clinical trials using allogeneic CART19 and discuss the future direction of the field.
窝转脊椎动物
发表于 2025-3-25 00:01:37
Margaret M. Stark,Guy A. Norfolkrs will be presented. These foundational concepts will be useful for understanding later chapters which largely deal with the purposeful engineering of immune cells for adoptive cellular therapies. An attempt has been made to highlight recent review articles for further reading, with an emphasis on those that involve tumor immunology.